Retina experts discuss the use of ranibizumab (Lucentis, Genentech) in the treatment of patients with wet age-related macular degeneration.
Participants include:
Julia A. Haller, MD (moderator), Professor and chairwoman, Department of Ophthalmology, Jefferson Medical College, Thomas Jefferson University Hospital, and ophthalmologist-in-chief, Wills Eye Institute, Philadelphia
Wilson Baber, MD, FACS, Private practice, Shreveport, LA
K. Bailey Freund, MD, VitreousRetinaMacula Consultants of New York
Jim Maisel, MD, FAAO, Private practice, Hicksville, NY
Jon Prenner, MD, RetinaVitreous Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical Center, New Brunswick, NJ
Rishi Singh, MD, Cole Eye Institute, Cleveland Clinic, Cleveland
In this first session, the experts discuss their standard approach when using ranibizumab (Lucentis, Genentech) to treat their patients with age-related macular degeneration.
In this second session, the retina experts discuss how they decide when they have obtained the best visual acuity for their patients and the role of optical coherence tomography in making those decisions.
In this third session, the physicians discuss how they communicate to their patients the increased risk of stroke that may be associated with dosing of anti-VEGF agents.
In this fourth session, the physicians discuss their strategies for managing the flow of patients coming in each month to receive their ranibizumab injections.
In this fifth session, the panel talks about intravitreal injection protocols and how they help to minimize complications such as endophthalmitis.
In this sixth session, hear the experts views on the use of bevacizumab and its related financial issues.
In this final roundtable session, the physicians discuss the future of AMD, including possible genetic testing for the disease, as well as how they manage patient expectations.
This program has been developed and provided by Ophthalmology Times, a publication of Advanstar Communications, Inc., which is solely responsible for its content.
Practice Tools
